M. Nielsen Hobbs
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From M. Nielsen Hobbs
Does the Trump-Cummings confab mean that drug makers are doomed to price negotiations in Medicare Part D? (Answer: Almost certainly not, but this is Trump we're talking about.)
Category is still in its infancy, but the newly renamed generic association worries that products might never reach their full potential if launches are substantially delayed by IP disputes.
How is the generic industry like Captain "Sully" trying to land a damaged plane in the Hudson River?
To call the incoming US president unpredictable would be an understatement, but that doesn’t mean that industry shouldn’t know what to expect.
Lame-duck passage is goal of changes to reform legislation, which now includes highly targeted funding for FDA.
A posting on the transition website takes a much milder tone than the GOP platform issued over the summer.